Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Columbia Labs

This article was originally published in The Tan Sheet

Executive Summary

Firm expands sales force to 135 people and is deploying group to detail its women's healthcare products. Offerings include Advantage-S spermicidal contraceptive and RepHresh Vaginal Gel marketed to OB/GYNs and other professional audiences, President & CEO Fred Wilkinson announces in Aug. 7 earnings call. The OTC products' Q2 sales helped boost Columbia's net revenues 36% to $4.9 mil. over Q1. Wilkinson predicts increased sales efforts behind Columbia's present products and launch of Rx Striant testosterone buccal system - which FDA approved June 19 - will allow the company to garner earnings, cash positive numbers by year end. Columbia posted a $4.4 mil. net loss in the second quarter...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS095786

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel